| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
23046 |
| Drug |
Dupilumab |
| Brand |
Dupixent® |
| Indication |
Dupilumab (Dupixent®) is indicated as an add-on therapy with intranasal corticosteroids, for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. |
| Rapid review commissioned |
25/07/2023 |
| Rapid review completed |
05/09/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dupilumab compared with the current standard of care for this indication, on the basis of the proposed price relative to currently available therapies. |
| Full pharmacoeconomic assessment commissioned by HSE |
28/09/2023 |
| Pre-submission consultation with Applicant |
11/12/2024 |
